Ethics of Drug Studies in the Newborn

Pediatric Drugs

Volumn 17, Issue 1, 2015, Pages 37-42

  Ward, Robert M ^a   Sherwin, Catherine M T ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMPHENICOL;

ARTICLE; BLOOD VOLUME; DRUG RESEARCH; HUMAN; HUMAN RIGHTS; MEDICAL ETHICS; NEWBORN; NEWBORN CARE; PARENTAL CONSENT; PEDIATRICS; PRIORITY JOURNAL; CLINICAL TRIAL (TOPIC); DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ETHICS; NEWBORN INTENSIVE CARE;

CLINICAL TRIALS AS TOPIC; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; INFANT, NEWBORN; INTENSIVE CARE UNITS, NEONATAL; PARENTAL CONSENT; PEDIATRICS;

EID: 84921835753     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.1007/s40272-014-0099-8     Document Type: Article

References (35)

1. Food and Drug Administration Modernization Act of 1997. (Public Law 105–115); 1997. Available from: http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/FDAMA/FullTextofFDAMAlaw/default.htm. Accessed 27 July 2014.
2. US Food and Drug Administration Safety and Innovation Act. (Public Law 112–144); 2012. Available from: http://www.gpo.gov/fdsys/pkg/PLAW-112publ144/pdf/PLAW-112publ144.pdf. Accessed 27 July 2014.
3. The European Parliament and the Council of the European Union. Paediatric Regulation (EC No 1901/2006). 2006. http://ec.europa.eu/health/human-use/paediatric-medicines/index_en.htm. Accessed 10 Oct 2014.
4. US Food and Drug Administration Pediatric Exclusivity Statistics. Last update July 28, 2014. Available from: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm050006.htm. Accessed 29 July 2014.
5. US Food and Drug Administration New Pediatric Labeling Information Database. Last update July 28, 2014. Available from: http://www.accessdata.fda.gov/scripts/sda/sdNavigation.cfm?sd=labelingdatabase. Accessed 28 July 2014.
6. Laughon MM, Avant D, Tripathi N, Hornik CP, Cohen-Wolkowiez M, Clark RH, et al. Drug labeling and exposure in neonates. JAMA Pediatr. 2014;168(2):130–6.
7. American Academy of Pediatrics Committee on Drugs. Uses of drugs not described in the package insert (off-label uses). Pediatrics. 2002;110(1 Pt 1):181–3.
8. Lebacqz K. Pediatric drug investigation: current ethical guidelines. In: Mirkin BL, editor. Clinical pharmacology and therapeutics, a pediatric perspective. Chicago: Year Book Medical Publishers, Inc.; 1978. p. 279–97.
9. Belmont Report: Ethical principles and guidelines for the protection of human subjects of research. Report of the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. 1979. Available from: http://www.hhs.gov/ohrp/humansubjects/guidance/belmont.html. Accessed 24 July 2014.
10. Guidelines for the ethical conduct of studies to evaluate drugs in pediatric populations. Committee on Drugs, American Academy of Pediatrics. Pediatrics. 1995;95(2):286–94.
11. Shaddy RE, Denne SC, Committee on Drugs and Committee on Pediatric Research. Clinical report—guidelines for the ethical conduct of studies to evaluate drugs in pediatric populations. Pediatrics. 2010;125(4):850–60.
12. Roth-Cline MD, Nelson RM. Ethical considerations in conducting pediatric research. In: Mulberg AE, Murphy D, Dunne J, Mathis LL, editors. Pediatric drug development, concepts and applications. Hoboken: Wiley; 2013. p. 83–97.
13. Simar MR. The consent and assent process in pediatric clinical trials. In: Mulberg AE, Murphy D, Dunne J, Mathis LL, editors. Pediatic drug development, concepts and applications. Hoboken: Wiley; 2013. p. 94–104.
14. The Spinal Muscular Atrophy Drug Development Pipeline. 2014 ‘Last Update’ January 22, 2014. Available from: http://www.fsma.org/Research/DrugPipeline/. Accessed 27 July 2014.
15. Burns LE, Hodgeman JE, Cass AB. Fatal and circulatory collapse in premature infants receiving chloramphenicol. N Engl J Med. 1959;261(26):1318–21.
16. International Congress on Harmonization: Clinical Investigation of Medicinal Products in the Paediatric Population. ICH E11. Last update 2001. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002926.pdf. Accessed 28 July 2014.
17. Mulberg AE, Murphy D, Dunne J, Mathis LL, editors. Pediatric drug development. Concepts and application. 2nd ed. Hoboken: Wiley; 2013.
18. US Food and Drug Administration Guidance for Industry Pediatric Study Plans: Content of and Process for Submitting Initial Pediatric Study Plans and Amended Pediatric Study Plans In: Services USDoHaH (ed). Washington, DC: 2013. p. 1–16.
19. Carlo WA, Finer NN, Walsh MC, Rich W, Gantz MG, Laptook AR, et al. Target ranges of oxygen saturation in extremely preterm infants. N Engl J Med. 2010;362(21):1959–69.
20. Resnik DB. What are reasonably foreseeable risks? Am J Bioeth. 2013;13(12):29–30.
21. Wilfond BS, Magnus D, Antommaria AH, Appelbaum P, Aschner J, Barrington KJ, et al. The OHRP and SUPPORT. N Engl J Med. 2013;368(25):e36.
22. Drazen JM, Solomon CG, Greene MF. Informed consent and SUPPORT. N Engl J Med. 2013;368(20):1929–31.
23. Hudson KL, Guttmacher AE, Collins FS. In support of SUPPORT—a view from the NIH. N Engl J Med. 2013;368(25):2349–51.
24. Tarnow-Mordi WO, Darlow B, Doyle L. Target ranges of oxygen saturation in extremely preterm infants. N Engl J Med. 2010;363(13):1285 (author reply -6).
25. Rocchi F, Tomasi P. The development of medicines for children. Part of a series on pediatric pharmacology, guest edited by Gianvincenzo Zuccotti, Emilio Clementi, and Massimo Molteni. Pharmacol Res. 2011;64(3):169–75.
26. Marsot A, Boulamery A, Bruguerolle B, Simon N. Population pharmacokinetic analysis during the first 2 years of life: an overview. Clin Pharmacokinet. 2012;51(12):787–98.
27. Millership JS. Microassay of drugs and modern measurement techniques. Paediatr Anaesth. 2011;21(3):197–205.
28. Alleman BW, Bell EF, Li L, Dagle JM, Smith PB, Ambalavanan N, et al. Individual and center-level factors affecting mortality among extremely low birth weight infants. Pediatrics. 2013;132(1):e175–84.
29. Allen MC, Donohue PK, Dusman AE. The limit of viability–neonatal outcome of infants born at 22–25 weeks’ gestation. N Engl J Med. 1993;329(22):1597–601.
30. Schlapbach LJ, Adams M, Proietti E, Aebischer M, Grunt S, Borradori-Tolsa C, et al. Outcome at two years of age in a Swiss national cohort of extremely preterm infants born between 2000 and 2008. BMC Pediatr. 2012;12:198.
31. Office for Health Research Protection (OHRP)—Categories of Research. Categories of research that may be reviewed by the Institutional Review Board (IRB) through an expedited review procedure. Categories of Research (2)(b). Last update 1998. Available from: http://www.hhs.gov/ohrp/policy/expedited98.html. Accessed 29 July 2014.
32. Smith PB, Cohen-Wolkowiez M, Castro LM, Poindexter B, Bidegain M, Weitkamp JH, et al. Population pharmacokinetics of meropenem in plasma and cerebrospinal fluid of infants with suspected or complicated intra-abdominal infections. Pediatr Infect Dis J. 2011;30(10):844–9.
33. Wade KC, Wu D, Kaufman DA, Ward RM, Benjamin DK Jr, Sullivan JE, et al. Population pharmacokinetics of fluconazole in young infants. Antimicrob Agents Chemother. 2008;52(11):4043–9.
34. Ward RM, Drover DR, Hammer GB, Stemland CJ, Kern S, Tristani-Firouzi M, et al. The pharmacokinetics of methadone and its metabolites in neonates, infants, and children. Paediatr Anaesth. 2014;24(6):591–601.
35. Kimko HC, Duffull SB. Simulation for designing clinical trials: a pharmacokinetic–pharmacodynamic modeling perspective. New York: Marcel Dekker; 2003.